Biobetters Market Size, Share & Industry Analysis, By Molecule Type (G-CSF Biobetters, Insulin Biobetters, Erythropoietin Biobetters, Monoclonal Antibodies Biobetters, Others), By Disease Indication (Cancer, Diabetes, Genetic disease, Neurological Disorders, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)and Regional Forecast, 2024-2032

Biobetters are biologically improved versiones of drugs that are already present in the market. Biobetters are different type of biosimilars that can be marketed after the innovator molecule loses it patent protection rights. CELLTRION INC. is currently developing an Antibody Drug Conjugate (ADC) biobetter that utilises Antibody- Delivery Enhancing Domain (ADED). This ADC product hat the company is developing is anticipated to help in the management of breast cancer patients. In the current market scenario, there are many bio-pharmaceutical companies that are setting to enter into biobetter development as it provides better investment opportunities. Biobetters are marketed as enhanced form of an innovator molecule hence has a better sales opportunity when compared with biosimilars.

Biobetters offer enhanced clinical efficacy and are classified as an improved form of innovator molecule. Owing to this, many biosimilars manufacturers are entering into the market of biobetters to capture customer base. Since there are not exact copies of innovator molecule, biobetters are entitled to patent protection up to 10 years. For example, Roche manufactured a biobetter of Epogen, named Mircera, to treat anemia caused by chronic kidney disease. In addition to providing higher efficacy, biobetters require lower duration for research and development when compared to its innovator products. These factors are anticipated to drive the market of biobetters over the forecast duration.

However, biobetters require twice as much more investment when compared to biosimilars. This is due to the fact that developing an enhanced version of an expired molecule is more complicated than developing an exact copy of the original molecule. This could restrain the market growth in the coming years.

Market Segmentation:

Globally, the Biobetters market can be segmented on the basis of products, operation, configuration, end-users, and region. Based on the molecule type, the market can be segmented into G-CSF biobetters, insulin biobetters, erythropoietin biobetters, monoclonal antibodies biobetters, and others. Based on the disease indication, the market can be segmented into cancer, diabetes, genetic disorders, neurological diseases, and others. Based on the distribution channel, the market can be categorised hospital pharmacy, retiail pharmacy, and online pharmacy.

Geographically, the biobetters market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the biobetters market are Novo Nordisk A/S, Eli Lily and Company, Amgen Inc., Merck & Co. Inc., Biogen Inc., F. Hoffman-LA Roche, Sanofi SA, Biogen Inc, Teva Pharmaceutical Industries Ltd., CSL Behring GmbH among other players.

Key Insights:

• Prevalence of Major Disease by Key Countries/Region


• Introduction of New Products/Approvals (By Major Players)


• Key Industry Developments Mergers, Acquisitions, and Collaborations


• Pipeline Analysis

Regional Analysis:

Geographically, the biobetters market can be categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North American region is likely to hold the largest share of the market and is anticipated to follow the same impetus over the forecast period. This is attributed to the higher prevalence of chronic disease such as cancer, diabetes, renal disease among others in the region. Combined with this, higher investment in R&D for therapeutic molecules and increased preference of key market players to seek regulatory approvals from healthcare authorities in U.S market is anticipated to drive the biobetters market in the region. Europe is projected to be the second most revenue generating market over the forecast duration. Advanced healthcare infrastructure, favorable reimbursement policies and active government funding in healthcare is projected to drive the market in the region. However, the biobetters market in countries such as China and India of the Asia-Pacific region is estimated to grow at a faster rate owing to increase in the prevalence of chronic disorders and rising geriatric population. The market in Latin America and the Middle East and Africa are expected to capture lower share in the global biobetters market.

Segmentation

Biobetters Market Industry Developments

• Green Cross Corp, one of the front runners in the competition in biobetters market is currently developing a biobetter of margetuximab in collaboration with American biotech MacroGenics.


• In the year 2017, HANALL BIOPHARMA in partnership with Ora Inc., submitted an application for Investigational new drug to the U.S Food and Drug Administration for their product named HL036, indicated to treat dry eye disease.